Condition:   Mucositis
Intervention:   Drug: Doxycycline hyclate
Sponsors:   Metropolitan Autonomous University;   Instituto Nacional de Cancerologia de Mexico
Not yet recruiting - verified March 2010

Conditions:   Leukemia;   Mucositis;   Oral Complications
Interventions:   Biological: epratuzumab;   Biological: palifermin;   Biological: rituximab;   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: daunorubicin hydrochloride;   Drug: etoposide;   Drug: fludarabine phosphate;   Drug: imatinib mesylate;   Drug: melphalan;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: nelarabine;   Drug: pegaspargase;   Drug: vincristine sulfate;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: assessment of therapy complications;   Radiation: total-body irradiation
Sponsor:   University College London Hospitals
Recruiting - verified March 2010

Conditions:   Larynx Cancer;   Lip Cancer;   Oral Cavity Cancer;   Pharyngeal Cancer;   Oropharyngeal Cancer
Intervention:  
Sponsor:   University of Kentucky
Recruiting - verified March 2010

Condition:   Oral Mucositis
Interventions:   Drug: amlexanox;   Drug: Vehicle rinse
Sponsors:   Access Pharmaceuticals, Inc.;   Advanced Clinical Research Services, LLC
Completed - verified March 2010

Condition:   Chronic Periodontitis
Intervention:   Biological: cell sheet pellets and cell sheet fragment
Sponsor:   Fourth Military Medical University
Active, not recruiting - verified October 2009

Condition:   Oral Lichen Planus
Interventions:   Drug: Minocycline;   Drug: Dexamethasone
Sponsor:   Sheba Medical Center
Not yet recruiting - verified March 2010

Condition:   Primary Sjögren Syndrome
Intervention:   Biological: blood sample
Sponsor:   University Hospital, Limoges
Recruiting - verified March 2010

Condition:   Sjogren's Syndrome
Intervention:   Drug: FID 114657 (ORB Preserved Ocular Emulsion)
Sponsor:   Alcon Research
Recruiting - verified March 2010

Conditions:   Squamous Cell Carcinoma of the Oral Cavity;   Oropharynx Metastases;   Lymph Metastases
Interventions:   Procedure: endoscopic examination;   Procedure: FDG-PET
Sponsor:   University Hospital, Ghent
Recruiting - verified March 2010

Condition:   Gingivitis
Interventions:   Drug: Marketed toothpaste;   Drug: Experimental toothpaste
Sponsor:   GlaxoSmithKline
Not yet recruiting - verified February 2010

Condition:   Hepatitis D, Chronic
Interventions:   Drug: peginterferon alfa-2a [Pegasys];   Drug: tenofovir;   Drug: placebo
Sponsor:   Hoffmann-La Roche
Recruiting - verified March 2010

Condition:   Prostate Cancer
Interventions:   Drug: Testosterone;   Drug: Etoposide
Sponsor:   Sidney Kimmel Comprehensive Cancer Center
Recruiting - verified March 2010

Condition:   Crohn´s Disease
Interventions:   Drug: budesonide;   Drug: budesonide
Sponsor:   Dr. Falk Pharma GmbH
Recruiting - verified March 2010

Condition:   Type 2 Diabetes
Intervention:   Drug: Intensive insulin
Sponsor:   Ohio University
Not yet recruiting - verified March 2010

Condition:   Kidney Stones
Intervention:   Drug: Sodium thiosulfate
Sponsor:   VA New York Harbor Healthcare System
Recruiting - verified March 2010

Condition:   Compensated Chronic Hepatitis B
Interventions:   Drug: lamivudine;   Drug: lamivudine;   Drug: lamivudine, adefovir
Sponsors:   Nanfang Hospital;   Ministry of Health, China;   GlaxoSmithKline
Recruiting - verified March 2010

Condition:   Colorectal Neoplasms
Interventions:   Drug: Glutamine;   Drug: Calcium and Magnesium
Sponsor:   Sanofi-Aventis
Recruiting - verified March 2010

Conditions:   Depression;   Major Depressive Disorder
Interventions:   Drug: F2695 SR;   Drug: Placebo
Sponsor:   Forest Laboratories
Recruiting - verified March 2010

Condition:   Chronic Obstructive Pulmonary Disease
Interventions:   Drug: PT003 MDI;   Drug: PT005 MDI;   Drug: Placebo MDI;   Drug: Tiotropium bromide 18 μg (Spiriva Handihaler®);   Drug: Formoterol Fumarate 12 μg (Foradil® Aerolizer®);   Drug: PT001 MDI
Sponsor:   Pearl Therapeutics, Inc.
Recruiting - verified March 2010

Condition:   Tobacco Dependence
Interventions:   Drug: Experimental Nicotine;   Drug: NiQuitinTM Nicotine Lozenge;   Drug: Nicorette® Nicotine Gum
Sponsor:   Johnson & Johnson Consumer & Personal Products Worldwide
Completed - verified March 2010

Condition:   Tobacco Dependence
Interventions:   Drug: Experimental Nicotine;   Drug: Nicotine Lozenge;   Drug: Nicotine gum
Sponsor:   Johnson & Johnson Consumer & Personal Products Worldwide
Completed - verified March 2010

Condition:   Primary Hyperparathyroidism
Intervention:   Procedure: Parathyroid surgery
Sponsor:   Region Skane
Not yet recruiting - verified March 2010

Conditions:   Healthy;   Diabetes Mellitus, Type 2
Interventions:   Drug: NN9925 (oral);   Drug: NN9925 (i.v.);   Drug: placebo;   Drug: NN9925 (oral);   Drug: placebo
Sponsor:   Novo Nordisk
Not yet recruiting - verified March 2010

Condition:   Diabetes Mellitus, Type 2
Intervention:   Other: Observational Study
Sponsors:   Bristol-Myers Squibb;   AstraZeneca;   University of Pennsylvania
Active, not recruiting - verified March 2010

Condition:   Diabetes Mellitus, Type 2
Intervention:   Other: Observational Study
Sponsors:   Bristol-Myers Squibb;   AstraZeneca;   University of Pennsylvania
Active, not recruiting - verified March 2010

Condition:   Alzheimer Disease
Interventions:   Drug: Acitretin;   Drug: Placebo
Sponsors:   Johannes Gutenberg University Mainz;   Alzheimer Forschungsinitiative e.V. (AFI)
Not yet recruiting - verified January 2010

Condition:   Diabetes Mellitus, Type 2
Intervention:   Other: Observational Study
Sponsors:   Bristol-Myers Squibb;   AstraZeneca;   University of Pennsylvania
Active, not recruiting - verified March 2010

Condition:   Diabetes Mellitus, Type 2
Intervention:   Other: Observational Study
Sponsors:   Bristol-Myers Squibb;   AstraZeneca;   University of Pennsylvania
Active, not recruiting - verified March 2010

Conditions:   Brain and Central Nervous System Tumors;   Leukemia;   Lymphoma;   Unspecified Childhood Solid Tumor, Protocol Specific
Interventions:   Drug: dexamethasone;   Drug: gamma-secretase inhibitor RO4929097;   Other: laboratory biomarker analysis;   Other: pharmacological study
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Not yet recruiting - verified March 2010

Condition:   Idiopathic Menorrhagia
Interventions:   Drug: Levonorgestrel (Mirena, BAY86-5028);   Drug: Hormonal treatment;   Drug: Antifibrinolytic treatment
Sponsor:   Bayer
Recruiting - verified March 2010

Condition:   Cardiovascular Disease
Interventions:   Drug: Active Clonidine;   Drug: Placebo Clonidine;   Drug: Active ASA;   Drug: Placebo ASA
Sponsor:   Hamilton Health Sciences
Not yet recruiting - verified March 2010

Condition:   Schizophrenia or Schizoaffective Disorder
Intervention:   Drug: Lurasidone
Sponsor:   Dainippon Sumitomo Pharma America
Completed - verified March 2010

Condition:   Constipation-predominant Irritable Bowel Syndrome
Intervention:   Drug: Lubiprostone
Sponsors:   Cedars-Sinai Medical Center;   Takeda Pharmaceuticals North America, Inc.
Not yet recruiting - verified December 2009

Condition:   Prostate Cancer
Interventions:   Drug: ABT-888;   Drug: temozolomide
Sponsor:   Abbott
Not yet recruiting - verified February 2010

Condition:   Metabolic Syndrome
Intervention:   Dietary Supplement: Armolipid Plus
Sponsors:   Rottapharm;   Federico II University
Recruiting - verified March 2010

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Linagliptin;   Drug: Placebo;   Drug: Glimepiride
Sponsor:   Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010

Condition:   Pharmacokinetics
Interventions:   Drug: colchicine 0.6 mg;   Drug: colchicine 0.6 mg;   Drug: colchicine;   Drug: colchicine;   Drug: colchicine
Sponsor:   Mutual Pharmaceutical Company, Inc.
Recruiting - verified March 2010

Conditions:   Ovarian;   Breast;   Prostate;   Pancreatic;   Advanced Tumours
Intervention:   Drug: olaparib
Sponsor:   AstraZeneca
Recruiting - verified March 2010

Condition:   Otitis Media With Effusion
Interventions:   Drug: Lansoprazole;   Drug: Placebo
Sponsors:   Hamilton Health Sciences;   McMaster University
Not yet recruiting - verified March 2010

Condition:   Postoperative Care
Interventions:   Other: Early oral feeding;   Other: Traditional Care
Sponsor:   Hospital General de Agudos “Dr. Cosme Argerich”
Recruiting - verified March 2010

Conditions:   Indolent Non-Hodgkin's Lymphoma;   Chronic Lymphocytic Leukemia
Interventions:   Drug: CAL-101;   Drug: Rituximab;   Drug: Bendamustine
Sponsor:   Calistoga Pharmaceuticals, Inc.
Not yet recruiting - verified March 2010

Conditions:   Atopic Dermatitis;   Psoriasis
Interventions:   Drug: Vitamin D3;   Drug: Placebo
Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   Food and Drug Administration (FDA);   University of California, San Diego
Completed - verified February 2010

Condition:   Ventilator Associated Pneumonia
Interventions:   Drug: 0.12% Chlorhexidine Digluconate;   Other: Toothbrushing
Sponsors:   Federal University of São Paulo;   Fundação de Amparo à Pesquisa do Estado de São Paulo
Completed - verified March 2009

Condition:   Lupus Arthritis
Interventions:   Drug: Laquinimod;   Drug: Laquinimod;   Other: Placebo
Sponsor:   Teva Pharmaceutical Industries
Not yet recruiting - verified March 2010

Condition:   Alzheimer's Disease
Interventions:   Drug: BMS-708163;   Drug: BMS-708163;   Drug: Placebo;   Drug: Placebo
Sponsor:   Bristol-Myers Squibb
Not yet recruiting - verified March 2010

Condition:   Prostate Cancer
Interventions:   Drug: Abiraterone Acetate;   Drug: Prednisone;   Drug: LHRHa
Sponsors:   M.D. Anderson Cancer Center;   Cougar Biotechnology, Inc.
Recruiting - verified March 2010

Conditions:   Peanut Hypersensitivity;   Food Hypersensitivity;   Immediate Hypersensitivity
Interventions:   Drug: Peanut powder;   Drug: Peanut extract;   Drug: Placebo extract;   Drug: Placebo powder
Sponsor:   Johns Hopkins University
Recruiting - verified March 2010

Condition:   Schizophrenia
Interventions:   Drug: paliperidone palmitate injection;   Drug: oral antipsychotics
Sponsor:   Janssen-Cilag International NV
Not yet recruiting - verified March 2010

Condition:   Fungal Infection
Interventions:   Drug: posaconazole;   Drug: Dextrose 5% in water (1) posaconazole (2);   Drug: posaconazole;   Drug: posaconazole;   Drug: posaconazole
Sponsor:   Schering-Plough
Not yet recruiting - verified February 2010

Condition:   Chronic Obstructive Pulmonary Disease
Intervention:   Drug: AZD5069
Sponsors:   AstraZeneca;   Quintiles
Recruiting - verified March 2010

Condition:   Clostridium Difficile Infection
Interventions:   Drug: MIYA-BM Fine Granules (CBM588);   Drug: Placebo Fine Granules (without CBM588)
Sponsor:   Osel, Inc.
Recruiting - verified February 2010

Conditions:   Skeletal Deformities;   Leg Length Discrepancy
Intervention:   Dietary Supplement: gastrolith calcium
Sponsor:   Hadassah Medical Organization
Not yet recruiting - verified February 2010

Conditions:   Chronic Kidney Failure;   Secondary Hyperparathyroidism
Intervention:  
Sponsor:   Abbott
Recruiting - verified March 2010

Condition:   Healthy Volunteers
Interventions:   Dietary Supplement: Single High Dose Cholecalciferol;   Dietary Supplement: Daily Dose Cholecalciferol
Sponsor:   Mayo Clinic
Recruiting - verified March 2010

Condition:   Schizophrenia
Interventions:   Drug: Risperidone;   Drug: Placebo;   Drug: LY2140023
Sponsor:   Eli Lilly and Company
Not yet recruiting - verified March 2010

Condition:   Colorectal Cancer
Interventions:   Drug: BMS-908662;   Drug: BMS-908662;   Drug: Cetuximab
Sponsors:   Bristol-Myers Squibb;   Genzyme
Not yet recruiting - verified March 2010

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: linagliptin;   Drug: placebo
Sponsor:   Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010

Condition:   Epilepsy
Intervention:   Drug: Intravenous Carbamazepine
Sponsor:   H. Lundbeck A/S
Completed - verified March 2010

Conditions:   HIV;   Infant, Newborn;   Anemia;   Neutropenia
Intervention:   Drug: cotrimoxazole
Sponsors:   Harvard School of Public Health;   National Institute of Allergy and Infectious Diseases (NIAID);   John E. Fogarty International Center (FIC);   Harvard Initiative for Global Health;   American Society of Tropical Medicine and Hygiene
Recruiting - verified March 2010

Condition:   Chronic Hepatitis B Virus, Pediatric
Interventions:   Drug: Entecavir;   Drug: Placebo
Sponsor:   Bristol-Myers Squibb
Not yet recruiting - verified March 2010

Condition:   Rotavirus Gastroenteritis
Interventions:   Biological: Placebo;   Biological: Rotarix ™
Sponsor:   GlaxoSmithKline
Not yet recruiting - verified March 2010

Condition:   Migraine
Interventions:   Drug: Rapimelt;   Drug: [11C]AZ10419369
Sponsor:   AstraZeneca
Not yet recruiting - verified March 2010

Condition:   Neuromuscular Disease
Interventions:   Drug: A0001 (alpha-tocopherolquinone);   Drug: Placebo
Sponsor:   Penwest Pharmaceuticals Co.
Recruiting - verified February 2010

Condition:   Peanut Allergy
Intervention:   Other: Peanut flour
Sponsor:   University of Texas Southwestern Medical Center
Enrolling by invitation - verified January 2010

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: AZD1656;   Drug: Gemfibrozil;   Drug: Placebo
Sponsor:   AstraZeneca
Not yet recruiting - verified March 2010

Conditions:   Secondary Hyperparathyroidism;   Chronic Kidney Disease
Intervention:   Drug: paricalcitol iv (Zemplar iv)
Sponsor:   Abbott
Active, not recruiting - verified March 2010

Condition:   Lupus Nephritis
Interventions:   Drug: laquinimod 0.5mg + standard of care;   Drug: laquinimod 1mg + standard of care;   Other: placebo + standard of care
Sponsor:   Teva Pharmaceutical Industries
Not yet recruiting - verified March 2010

Condition:   Pancreatic Cancer
Intervention:   Biological: PANC 10.05 pcDNA-1/GM-Neo and PANC 6.03 pcDNA-1 neo vaccine.
Sponsor:   Sidney Kimmel Comprehensive Cancer Center
Not yet recruiting - verified March 2010

Condition:   Chronic Lymphocytic Leukemia
Interventions:   Drug: ABT-263;   Drug: rituximab
Sponsors:   Genentech;   Abbott
Not yet recruiting - verified March 2010

Condition:   Human Immunodeficiency Virus-Associated Adipose Redistribution Syndrome
Intervention:   Biological: Serostim
Sponsor:   EMD Serono
Completed - verified March 2010

Condition:   Acne
Intervention:   Drug: apremilast
Sponsors:   The University of North Carolina, Chapel Hill;   Celgene Corporation
Recruiting - verified February 2010

Condition:   Gaucher Disease
Interventions:   Drug: Genz-112638;   Drug: Genz-112638
Sponsor:   Genzyme
Not yet recruiting - verified January 2010

Condition:   Anaemia
Interventions:   Drug: IV trivalent saccharose hydroxide ferrous;   Drug: Oral ferrous fumarate;   Drug: Oral and intravenous Placebo
Sponsor:   Fundación Canaria Rafael Clavijo para la Investigación Biomédica
Completed - verified May 2007

Condition:   Haematological Malignancies
Interventions:   Drug: AS703569;   Drug: AS703569
Sponsor:   EMD Serono
Active, not recruiting - verified March 2010

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: pioglitazone/rosiglitazone/placebo;   Drug: rosiglitazone/pioglitazone/placebo;   Drug: placebo/pioglitazone/rosiglitazone;   Drug: pioglitazone/placebo/rosiglitazone;   Drug: rosiglitazone/placebo/pioglitazone;   Drug: placebo/rosiglitazone/pioglitazone
Sponsor:   Solvay Pharmaceuticals
Completed - verified March 2010

Condition:   Intubation, Gastrointestinal
Interventions:   Drug: Lignocaine;   Drug: Placebo
Sponsor:   Queensland Children's Medical Research Institute
Not yet recruiting - verified February 2010

Condition:   Multiple Myeloma and Plasma Cell Neoplasm
Interventions:   Drug: bortezomib;   Drug: dexamethasone;   Drug: melphalan
Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
Not yet recruiting - verified February 2010

Condition:   Retinopathy of Prematurity
Intervention:   Drug: Propranolol
Sponsors:   Azienda Ospedaliero, Universitaria Meyer;   Ospedale Maggiore Policlinico Mangiagalli e Regina Elena
Recruiting - verified February 2010

Condition:   Diabetes in Cystic Fibrosis Patients
Intervention:   Other: Prospective cohort with an annual follow-up
Sponsor:   Hospices Civils de Lyon
Recruiting - verified October 2009

Conditions:   Cancer;   Solid Tumors;   Lymphoma;   Malignancy
Intervention:   Drug: AT-406
Sponsor:   Ascenta Therapeutics
Recruiting - verified March 2010

Condition:   Metastatic Colorectal Cancer
Interventions:   Drug: Mek Inhibitor MSC1936369B;   Drug: Mek Inhibitor MSC1936369B;   Drug: Placebo;   Drug: FOLFIRI
Sponsor:   EMD Serono
Recruiting - verified March 2010

Condition:   Knee Osteoarthritis
Interventions:   Dietary Supplement: Glucosamine sulphate;   Other: Placebo
Sponsor:   University of British Columbia
Not yet recruiting - verified February 2010

Condition:   Small Bowel Obstruction
Interventions:   Drug: Somatostatin;   Other: common daily practice
Sponsor:   Nanjing PLA General Hospital
Not yet recruiting - verified February 2010

Condition:   Myelodysplastic Syndrome
Intervention:   Drug: Erlotinib
Sponsors:   Groupe Francophone des Myelodysplasies;   Roche Pharma AG
Active, not recruiting - verified March 2010

Condition:   Major Depressive Disorder
Interventions:   Drug: Duloxetine;   Drug: Placebo
Sponsor:   Eli Lilly and Company
Not yet recruiting - verified February 2010

Condition:   Hematologic Malignancies
Intervention:   Other: TOTAL LYMPHOID IRRADIATION
Sponsor:   Fondazione Neoplasie Sangue Onlus
Recruiting - verified March 2010

Condition:   Hepatitis C, Chronic
Interventions:   Drug: Drug: SCH 900518 Biologic: Peginterferon alfa-2b(PegIntron);   Drug: Drug: SCH 900518 Biologic: Peginterferon alfa-2b;   Drug: Drug: SCH 900518 Drug: Ritonavir (RTV) Biologic: Peginterferon alfa-2b (PegIntron);   Drug: Drug: SCH 900518 Drug: Ritonavir (RTV) Drug: Ritonavir (RTV) Biologic: Peginterferon alfa-2b (PegIntron)
Sponsor:   Schering-Plough
Completed - verified March 2010

Condition:   Metastatic Pancreatic Cancer
Intervention:   Drug: Gemcitabine, nab-Paclitaxel, GDC-0449
Sponsors:   Sidney Kimmel Comprehensive Cancer Center;   Stand Up To Cancer;   Genentech;   Abraxis BioScience Inc.
Not yet recruiting - verified March 2010

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: AZD1656;   Drug: Pioglitazone
Sponsor:   AstraZeneca
Recruiting - verified March 2010

Conditions:   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Hepatosplenic T-cell Lymphoma;   Nodal Marginal Zone B-cell Lymphoma;   Peripheral T-Cell Lymphoma;   Post-transplant Lymphoproliferative Disorder;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Splenic Marginal Zone Lymphoma;   Waldenstrom Macroglobulinemia
Interventions:   Drug: everolimus;   Drug: lenalidomide;   Other: laboratory biomarker analysis;   Genetic: polymorphism analysis;   Other: immunohistochemistry staining method;   Genetic: microarray analysis;   Genetic: fluorescence in situ hybridization
Sponsor:   Mayo Clinic
Not yet recruiting - verified February 2010

Conditions:   Renal Insufficiency;   Secondary Hyperparathyroidism
Intervention:   Drug: Zemplar (paricalcitol)
Sponsor:   Abbott
Recruiting - verified March 2010

Condition:   Diabetes Type 2
Interventions:   Drug: Insulin-Levemir;   Drug: Exenatide-Bayetta;   Drug: Insulin-Levemir and Exenatide-Bayetta;   Device: SenseWear Pro3® armband;   Device: DexCom CGM
Sponsors:   Novo Nordisk;   BodyMedia
Recruiting - verified June 2009

Conditions:   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With T(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With T(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With T(8;21)(q22;q22);   Childhood Myelodysplastic Syndromes;   Chronic Myelomonocytic Leukemia;   Previously Treated Myelodysplastic Syndromes;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndromes
Interventions:   Drug: azacitidine;   Drug: gemtuzumab ozogamicin
Sponsor:   Fred Hutchinson Cancer Research Center
Not yet recruiting - verified March 2010

Condition:   Heart Failure
Intervention:   Drug: AMG 423
Sponsor:   Amgen
Not yet recruiting - verified February 2010

Condition:   Breast Cancer
Interventions:   Drug: XL147;   Drug: XL765;   Drug: letrozole (Femara)
Sponsor:   Exelixis
Not yet recruiting - verified March 2010

Condition:   Advanced Renal Cell Carcinoma
Interventions:   Drug: Tivozanib;   Drug: Sorafenib
Sponsor:   AVEO Pharmaceuticals, Inc.
Not yet recruiting - verified February 2010

Condition:   Hypercholesterolemia
Intervention:   Drug: Simvastatin
Sponsor:   Hadassah Medical Organization
Not yet recruiting - verified March 2010

Condition:   Bone-Metastatic, Castration-Resistant Prostate Cancer
Intervention:   Drug: KX2-391
Sponsor:   Kinex Pharmaceuticals, LLC
Recruiting - verified March 2010

Conditions:   Male Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer
Interventions:   Drug: vorinostat;   Drug: ixabepilone
Sponsor:   City of Hope Medical Center
Not yet recruiting - verified March 2010

Condition:   Non-small Cell Lung Cancer
Interventions:   Drug: Imatinib Mesylate;   Drug: Docetaxel
Sponsors:   M.D. Anderson Cancer Center;   Novartis
Active, not recruiting - verified March 2010

Condition:   Hepatitis C
Interventions:   Drug: ABT-072;   Drug: Placebo
Sponsors:   Abbott;   Abbott Japan Co.,Ltd
Not yet recruiting - verified February 2010

Conditions:   Wounds and Injuries;   Wound Healing;   Ulcer
Intervention:  
Sponsor:   National Institute of Dental and Craniofacial Research (NIDCR)
Recruiting - verified November 2009

Condition:   Female Breast Cancer
Intervention:   Drug: Estradiol
Sponsor:   University of Wisconsin, Madison
Recruiting - verified March 2010

Conditions:   Cannabis Use;   Drug Abuse
Intervention:   Drug: Cannabis Cigarette
Sponsor:   National Institute on Drug Abuse (NIDA)
Recruiting - verified December 2009

Condition:   Hypertension
Interventions:   Drug: Azilsartan medoxomil (TAK-491);   Drug: Azilsartan medoxomil (TAK-491);   Drug: Azilsartan medoxomil (TAK-491);   Drug: Azilsartan medoxomil (TAK-491)
Sponsor:   Takeda Global Research & Development Center, Inc.
Not yet recruiting - verified February 2010

Conditions:   Alzheimer's Disease;   Central Nervous System Diseases;   Cognition
Interventions:   Drug: EVP-6124;   Drug: Placebo
Sponsors:   EnVivo Pharmaceuticals, Inc.;   INC Research Limited
Not yet recruiting - verified February 2010

Condition:   Schizophrenia
Interventions:   Drug: MS14;   Drug: Risperidone
Sponsor:   Farzan Institute
Recruiting - verified February 2010

Condition:   Schizophrenia
Intervention:   Drug: Lurasidone HCl
Sponsor:   Dainippon Sumitomo Pharma America
Completed - verified February 2010

Condition:   Lower Respiratory Tract Infection
Intervention:   Drug: clarithromycin (Klacid®) granules for oral suspension
Sponsor:   Abbott
Recruiting - verified February 2010

Condition:   Hemangioma
Interventions:   Drug: Propranolol;   Drug: Prednisone
Sponsors:   University of Sao Paulo;   University of Sao Paulo General Hospital
Recruiting - verified December 2009

Condition:   Non-small Cell Lung Cancer
Interventions:   Drug: RO4929097;   Drug: RO4929097
Sponsor:   Hoffmann-La Roche
Recruiting - verified February 2010

Condition:   PROSTATE CANCER.
Interventions:   Drug: Docetaxel and Prednisone;   Drug: Docetaxel and Prednisone;   Drug: Radiation Therapy
Sponsors:   Northwestern University;   Genzyme
Not yet recruiting - verified March 2010

Conditions:   Chronic Myeloid Leukemia;   Acute Lymphoblastic Leukemia
Intervention:   Drug: Nilotinib
Sponsor:   Novartis Pharmaceuticals
Not yet recruiting - verified February 2010

Conditions:   Renal Impairment;   Hemodialysis;   Anemia
Intervention:   Drug: ASP1517
Sponsor:   Astellas Pharma Inc
Recruiting - verified March 2010

Conditions:   Blood Stream Infections;   Candida
Intervention:  
Sponsors:   University of Houston;   Merck
Active, not recruiting - verified January 2010

Conditions:   Myeloma;   Stem Cell Transplantation
Interventions:   Drug: Lenalidomide;   Drug: Melphalan
Sponsor:   M.D. Anderson Cancer Center
Recruiting - verified March 2010

Condition:   Autistics Children
Intervention:   Drug: bumetanide
Sponsor:   University Hospital, Brest
Active, not recruiting - verified March 2010

Condition:   Bowel Preparation
Interventions:   Drug: PicoPrep;   Drug: HalfLytely
Sponsor:   Ferring Pharmaceuticals
Not yet recruiting - verified February 2010

Conditions:   Allergic Rhinoconjunctivitis;   Chronic Urticaria
Intervention:   Drug: Bilastine
Sponsor:   Faes Farma, S.A.
Recruiting - verified March 2010

Conditions:   Malnutrition;   Aged
Interventions:   Dietary Supplement: Standard ONS (Fortisip, Fortisp Extra or Fortisip Multifibre);   Dietary Supplement: High Energy, low volume ONS (Cooper, Cooper Fibre, Cooper Protein)
Sponsor:   Nutricia UK Ltd
Recruiting - verified March 2010

Condition:   Bladder Cancer
Interventions:   Drug: Bacille Calmette-Guerin;   Drug: uracil-tegafur
Sponsor:   Urological Oncology Council of Northern Tokyo
Recruiting - verified March 2010

Condition:   Capsular Contractures
Intervention:   Drug: Trental
Sponsor:   Legacy Health System
Recruiting - verified March 2010

Condition:   Hepatitis C Recurrence
Intervention:   Drug: Nitazoxanide
Sponsor:   Mayo Clinic
Recruiting - verified February 2010

Condition:   Endometrial Hyperplasia
Interventions:   Drug: Provera (medroxyprogesterone/progestin);   Drug: Provera (medroxyprogesterone);   Device: Mirena (levonorgestrel)
Sponsors:   University Hospital of North Norway;   Helse Nord;   Norwegian Cancer Society
Recruiting - verified February 2010

Condition:   Fibromyalgia
Interventions:   Drug: Placebo;   Drug: Milnacipran
Sponsors:   Forest Laboratories;   Cypress Bioscience, Inc.
Recruiting - verified February 2010

Conditions:   C. Trachomatis;   Gonococcal Infections
Interventions:   Drug: Azithromycin;   Drug: Placebo;   Drug: Cefixime
Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting - verified February 2010

Condition:   Ovarian Cancer
Interventions:   Drug: olaparib;   Drug: paclitaxel;   Drug: carboplatin
Sponsor:   AstraZeneca
Recruiting - verified March 2010

Condition:   Familial Hypercholesterolaemia
Interventions:   Drug: rosuvastatin calcium;   Drug: rosuvastatin calcium;   Drug: rosuvastatin calcium
Sponsor:   AstraZeneca
Recruiting - verified March 2010

Condition:   Waldenstrom's Macroglobulinemia
Interventions:   Drug: pomalidomide;   Drug: dexamethasone;   Drug: rituximab
Sponsors:   Dana-Farber Cancer Institute;   Celgene Corporation
Not yet recruiting - verified March 2010

Conditions:   Hyperuricosuria;   Kidney Stones
Interventions:   Drug: Febuxostat;   Drug: Allopurinol;   Drug: Placebo
Sponsor:   Takeda Global Research & Development Center, Inc.
Not yet recruiting - verified February 2010

Conditions:   Busulfan Pharmacokinetic Analysis;   GST Genetic Polymorphism
Intervention:   Drug: Hematological Stem Cell Transplantation
Sponsors:   Rambam Health Care Campus;   Israel Cancer Association
Recruiting - verified May 2009

Conditions:   Non-small Cell Lung Cancer;   EGFR Mutations
Intervention:   Drug: BIBW 2992
Sponsors:   Massachusetts General Hospital;   Dana-Farber Cancer Institute;   Beth Israel Deaconess Medical Center;   Boehringer Ingelheim Pharmaceuticals
Not yet recruiting - verified February 2010

Conditions:   Respiratory Tract Infections;   Influenza
Interventions:   Dietary Supplement: Cholecalciferol (Vitamin D/Vigantol oil);   Dietary Supplement: Miglyol oil
Sponsors:   Barts & The London NHS Trust;   National Health Service, United Kingdom
Not yet recruiting - verified February 2010

Conditions:   Castrate-Resistant Prostate Cancer;   Hormone Refractory Prostate Cancer
Interventions:   Drug: custirsen sodium;   Drug: Isotonic, 0.9% sodium chloride
Sponsors:   OncoGenex Technologies;   Teva Pharmaceuticals USA
Not yet recruiting - verified March 2010

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: ASP1941;   Drug: Metformin;   Drug: Placebo
Sponsor:   Astellas Pharma Inc
Recruiting - verified March 2010

Condition:   Community Acquired Pneumonia
Interventions:   Drug: Zabofloxacin;   Drug: Levofloxacin 500mg;   Drug: Zabofloxacin 400mg
Sponsor:   Pacific Beach BioSciences, Inc.
Not yet recruiting - verified March 2010

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: NN1250;   Drug: insulin glargine
Sponsor:   Novo Nordisk
Recruiting - verified March 2010

Condition:   Colorectal Cancer
Intervention:   Dietary Supplement: vitamin D repletion with Cholecalciferol (vitamin D3 50,000 International Units)
Sponsor:   Memorial Sloan-Kettering Cancer Center
Recruiting - verified February 2010

Condition:   Primary Systemic Amyloidosis
Interventions:   Drug: bortezomib;   Drug: cyclophosphamide;   Drug: dexamethasone
Sponsor:   Mayo Clinic
Not yet recruiting - verified February 2010

Condition:   Familial Mediterranean Fever
Interventions:   Drug: colchicine sprinkle capsules;   Drug: colchicine sprinkle capsules
Sponsor:   Mutual Pharmaceutical Company, Inc.
Not yet recruiting - verified March 2010

Condition:   Diabetes Mellitus
Interventions:   Drug: BGP-15 100 mg QD;   Drug: BGP-15 100 mg BID;   Drug: Placebo BID;   Drug: BGP-15 200 mg QD;   Drug: BGP-15 200 mg BID;   Drug: BGP-15 400 mg QD
Sponsors:   N-Gene Research Laboratories, Inc.;   Integrium;   Msource Medical Development GmbH;   Kinexum LLC;   Fisher Clinical Services UK Ltd;   Haupt Pharma Wülfing GmbH;   BARC nv
Not yet recruiting - verified February 2010

Condition:   Uremic Pruritus
Interventions:   Drug: Pregabalin;   Drug: Placebo
Sponsor:   Shaare Zedek Medical Center
Not yet recruiting - verified February 2010

Conditions:   HIV;   HIV Infections
Intervention:   Drug: darunavir/ritonavir then atazanavir/ritonavir
Sponsor:   St Stephens Aids Trust
Not yet recruiting - verified February 2010

Condition:   Chronic Urticaria
Interventions:   Drug: Placebo;   Drug: Hydroxychloroquine
Sponsor:   Vanderbilt University
Not yet recruiting - verified February 2010

Condition:   HCV Infection
Interventions:   Drug: GS-9256;   Drug: GS-9190;   Drug: Ribavirin
Sponsor:   Gilead Sciences
Recruiting - verified March 2010

Condition:   Breast Cancer
Intervention:   Drug: letrozole
Sponsors:   University of Arizona;   National Cancer Institute (NCI)
Not yet recruiting - verified February 2010

Condition:   Enteritis
Intervention:   Drug: DOR201 (delayed release beclomethasone dipropionate)
Sponsors:   Soligenix;   National Cancer Institute (NCI)
Recruiting - verified February 2010

Conditions:   Multiple Sclerosis;   Optic Neuritis;   Minocycline
Intervention:   Drug: Minocycline
Sponsors:   University of Calgary;   Neuroscience Canada
Recruiting - verified February 2010

Condition:   Dental Pain
Interventions:   Drug: Monographed toothpaste;   Device: Occlusion Product 2;   Device: Placebo;   Other: Occlusion Product 1
Sponsor:   GlaxoSmithKline
Completed - verified February 2010

Conditions:   Diarrhea;   Acute Respiratory Infection
Interventions:   Dietary Supplement: milk supplement 1;   Dietary Supplement: milk supplement 2
Sponsors:   Nestlé Nutrition Corporate;   University of the Philippines
Not yet recruiting - verified February 2010

Conditions:   Acute on Chronic Liver Failure;   Hepatitis B
Intervention:   Drug: Tenofovir disoproxil fumarate (TDF)
Sponsor:   Govind Ballabh Pant Hospital
Completed - verified October 2009

Condition:   Gastroparesis
Interventions:   Drug: [2-13C] uracil;   Drug: [2-13C] uracil, placebo
Sponsor:   Otsuka Pharmaceutical Co., Ltd.
Recruiting - verified February 2010

Condition:   Acute Respiratory Distress Syndrome
Intervention:   Other: intensive medical nutrition therapy
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Enrolling by invitation - verified November 2009

Condition:   Multiple Myeloma de Novo Treatment
Interventions:   Drug: Thalidomide, Dexamethasone;   Drug: Vincristin , Adriamycin, Dexamethasone = VAD;   Drug: Thalidomide, melphalan, endoxan, dexamethasone (MCDex-Thal);   Drug: melphalan, endoxan, dexamethasone (MCDex);   Drug: Thalidomide, Dexamethasone
Sponsors:   University Hospital, Caen;   Laphal
Completed - verified February 2010

Condition:   Healthy
Interventions:   Drug: AZD6765;   Drug: midazolam
Sponsor:   AstraZeneca
Recruiting - verified February 2010

Condition:   Type 2 Diabetes
Intervention:   Dietary Supplement: Isomaltulose
Sponsors:   University of Giessen;   Numico Research
Completed - verified November 2002

Condition:   Liver Cancer
Interventions:   Drug: sorafenib tosylate;   Drug: vorinostat
Sponsors:   Virginia Commonwealth University;   Massey Cancer Center
Not yet recruiting - verified March 2010

Condition:   Cytomegalovirus Infection
Interventions:   Biological: Adoptive Cellular Therapy;   Drug: Best available antiviral drug therapy
Sponsors:   Cell Medica Ltd;   Wellcome Trust;   Choice Pharma Ltd;   Commitum AB;   BioAnaLab
Recruiting - verified February 2010

Condition:   Becker Muscular Dystrophy
Interventions:   Drug: Tadalafil;   Drug: Placebo
Sponsors:   Cedars-Sinai Medical Center;   Muscular Dystrophy Association
Recruiting - verified March 2010

Condition:   Heart Failure, Congestive
Intervention:   Drug: Bisoprolol
Sponsor:   Merck KGaA
Recruiting - verified February 2010

Conditions:   The Null Hypothesis is That Food Rheology Will Have no Effect on These Indices.;   The Alternate Hypothesis is That Increased Mechanical Stimulation Will Result in Stronger Satiation/Satiety and Reduced Energy Intake.;   Further, it is Hypothesized That the Effects of Mastication Will be Less Evident in Obese Compared to Lean Individuals.
Interventions:   Other: soft gum;   Other: firm gum;   Other: no gum
Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Not yet recruiting - verified February 2010

Condition:   Non-Small-Cell Lung Cancer
Intervention:   Drug: ARQ 197 and Erlotinib
Sponsor:   Kyowa Hakko Kirin Company, Limited
Recruiting - verified February 2010

Condition:   Paroxysmal Atrial Fibrillation
Interventions:   Drug: Dronedarone;   Drug: Placebo
Sponsor:   Eastbourne General Hospital
Not yet recruiting - verified February 2010

Condition:   Glucose Lowering
Intervention:   Drug: AZD1656
Sponsor:   AstraZeneca
Not yet recruiting - verified February 2010

Condition:   Peanut Allergy
Intervention:   Drug: Trichuris suis ova (TSO)
Sponsors:   Beth Israel Deaconess Medical Center;   Food Allergy Initiative
Recruiting - verified February 2010